NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

TY - JOUR

T1 - NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma

AU - Gilbert, Mark R.

AU - Pugh, Stephanie L.

AU - Aldape, Ken

AU - Sorensen, A. Gregory

AU - Mikkelsen, Tom

AU - Penas-Prado, Marta

AU - Bokstein, Felix

AU - Kwok, Young

AU - Lee, R. Jeffrey

AU - Mehta, Minesh

N1 - Angiogenesis, a hallmark of glioblastoma, can potentially be targeted by inhibiting the VEGF pathway using bevacizumab, a humanized monoclonal antibody against VEGF-A. This study was designed to determine the efficacy and safety of these regimens in the cooperative group setting. Eligibility included age ≥18, recurrent or progressive GBM after standard chemoradiation.

PY - 2017/1/1

Y1 - 2017/1/1

UR - https://link.springer.com/article/10.1007/s11060-016-2288-5

U2 - 10.1007/s11060-016-2288-5

DO - 10.1007/s11060-016-2288-5

M3 - Article

VL - 131

JO - Journal of neuro-oncology

JF - Journal of neuro-oncology

ER -